Authors

Latest:

There's an App for That: Keeping Patients and Physicians on Track

In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.

Janice M. Mehnert, MD

Janice M. Mehnert, MD, is a professor in the Department of Medicine at NYU Grossman School of Medicine, director of the Melanoma Medical Oncology Program, and associate director of Clinical Research at Perlmutter Cancer Center in New York City.

Latest:

Dr Mehnert on Next Steps for the Evaluation of Quadruplet Therapy in Advanced Melanoma

Janice M. Mehnert, MD, discusses the ongoing investigation of sarilumab plus ipilimumab, nivolumab, and relatlimab in unresectable stage III/IV melanoma.

Janice Mehnert, MD

Latest:

Dr. Janice Mehnert on Why it's a Challenge to Identify Biomarkers for Immunotherapy

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents.

Janice P. Dutcher, MD, Cytokine Working Group

Janice Shen, MD

Latest:

Overcoming Burnout as an Oncology Fellow

Janice Shen, MD, provides advice on how to overcome burnout in order to provide the best care possible for patients with cancer.

Janos L. Tanyi, MD, PhD

Latest:

Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian Cancer

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Jared M. Weiss, MDUniversity of North Carolina School of Medicine

Jared Weiss, MD

Latest:

Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCC

Jared Weiss, MD, discusses outcomes with first-line Versamune HPV plus pembrolizumab in HPV16–positive recurrent or metastatic HNSCC.

Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center

Latest:

Major Advances in RET Inhibition for NSCLC and MTC

Jared Weiss, MD, UNC School of Medicine

Jared Weiss, MD, University of North Carolina School of Medicine

Jaron Mark, MD

Latest:

Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative Patients

Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.

Jaroslaw P. Maciejewski, MD, PhD

Latest:

Dr. Maciejewski on Impact of Eltrombopag on Expansion of Clones in Refractory Aplastic Anemia

Jaroslaw P. Maciejewski, MD, PhD, chair, Department of Translational Hematology and Oncology Research, Cleveland Clinic, discusses the impact of eltrombopag on an expansion of clones with somatic mutations in patients with refractory aplastic anemia.

Jarrod Longcor, MS, MBA

Latest:

The Potential Utility of CLR 131 in Multiple Myeloma

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Jarushka Naidoo, MBBCh

Latest:

Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr Naidoo

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

Latest:

“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting

Jarushka Naidoo, MD, BCh

Latest:

Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors

Jarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Jasgit Sachdev, MD

Latest:

Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.

Jashodeep Datta, MD

Latest:

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.

Jasmeet C. Singh, MD

Latest:

Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.